Online citations, reference lists, and bibliographies.

Systemic Interventions For Treatment Of Stevens‐Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), And SJS/TEN Overlap Syndrome

A. Langley, B. Worley, J. Pardo, J. Beecker, T. Ramsay, Arturo Saavedra, Jean Farrell-McCawley, P. Tugwell
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1111/j.1365-2133.2005.06721.x
Toxic epidermal necrolysis: current evidence, practical management and future directions
T. Chave (2005)
10.1001/archderm.1993.01680220104023
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
S. Bastuji-Garin (1993)
10.4103/0378-6323.116738
Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid.
G. Singh (2013)
10.1001/ARCHDERM.139.1.26
Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.
C. Prins (2003)
10.1056/NEJM199512143332404
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
J. Roujeau (1995)
10.1111/pde.12029
Toxic epidermal necrolysis in a child successfully treated with infliximab.
V. Scott-Lang (2014)
10.1111/j.1365-2133.2010.09863.x
Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis
L. Valeyrie-Allanore (2010)
10.2340/00015555-0462
Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis.
Agnieszka Wojtkiewicz (2008)
10.1136/bmj.i4919
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
J. Sterne (2016)
10.1073/PNAS.0409500102
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
S. Hung (2005)
10.1111/epi.12217
HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese
Ying-Kit Cheung (2013)
10.1016/j.jaad.2015.08.008
Treatment of toxic epidermal necrolysis in North America.
R. Dodiuk-Gad (2015)
10.1067/MJD.2002.127249
Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children.
P. Tristani-Firouzi (2002)
Cyclosporine for SJS/TEN: a case series and review of the literature.
Drew A. Reese (2011)
10.1097/00005373-200003000-00017
Treatment of toxic epidermal necrolysis with cyclosporin A.
J. Arévalo (2000)
10.1016/j.jid.2017.05.022
Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches.
C. González‐Herrada (2017)
10.1038/428486A
Medical genetics: A marker for Stevens–Johnson syndrome
Wen-hung Chung (2004)
Chapter 10: Addressing reporting biases
M. Egger (2011)
10.1016/j.jid.2017.12.034
Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses.
F. Poizeau (2018)
10.1345/APH.1K001
Etanercept for Toxic Epidermal Necrolysis
G. Famularo (2007)
10.1111/j.1440-0960.1996.tb01057.x
Lamotrigine‐induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management
J. Sullivan (1996)
10.1016/j.jtos.2015.10.002
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease.
Sahar Kohanim (2016)
10.1001/ARCHDERM.139.1.39
Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience.
J. Trent (2003)
10.1001/jamadermatol.2016.5668
Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis
S. Zimmermann (2017)
10.1016/j.jaad.2011.11.707
Toxic epidermal necrolysis successfully treated with infliximab.
L. C. Zárate-Correa (2013)
10.1001/archderm.1987.01660330071012
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.
J. Revuz (1987)
10.1126/SCIENCE.282.5388.490
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
I. Viard (1998)
10.1002/14651858.CD001435
Interventions for toxic epidermal necrolysis.
S. Majumdar (2002)
10.1046/J.1523-1747.2000.00061.X
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.
S. Bastuji-Garin (2000)
10.1159/000051702
Toxic Epidermal Necrolysis Treated with Intravenous High-Dose Immunoglobulins: Our Experience
M. Stella (2001)
10.1016/j.alit.2015.09.001
Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
Y. Yamane (2016)
10.1038/nm1208-1311
Saving the skin from drug-induced detachment
B. Nickoloff (2008)
10.2165/00003495-200565150-00002
Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg)
O. Faye (2012)
10.1111/j.1600-0625.1995.tb00211.x
Low N‐acetylating capacity in patients with Stevens‐Johnson syndrome and toxic epidermal necrolysis *
A. Dietrich (1995)
10.1111/j.1365-2133.1995.tb02649.x
Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin
I. Zaki (1995)
10.1016/j.jaad.2014.04.044
Etanercept therapy for toxic epidermal necrolysis.
A. Paradisi (2014)
10.1111/j.1346-8138.2009.00616.x
Toxic epidermal necrolysis successfully treated with etanercept
E. Gubinelli (2009)
10.1016/j.jaad.2013.07.036
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases.
M. Napolitano (2013)
10.1111/ijd.12702
Stevens–Johnson syndrome and toxic epidermal necrolysis: a 20‐year single‐center experience
Jovan Lalosevic (2015)
10.4103/0378-6323.110749
A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population.
T. Patel (2013)
Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF.
E. Robak (2001)
10.1111/J.1365-2230.1997.TB01044.X
Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor
P. Jarrett (1997)
10.1155/2012/915314
Combination of Infliximab and High-Dose Intravenous Immunoglobulin for Toxic Epidermal Necrolysis: Successful Treatment of an Elderly Patient
Konstantinos Patmanidis (2012)
10.1016/j.jid.2016.03.023
Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.
D. Hsu (2016)
10.1001/archderm.1991.01680050075007
A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures.
B. Strom (1991)
10.1172/JCI93349
Randomized, controlled trial of TNF-&agr; antagonist in CTL-mediated severe cutaneous adverse reactions
C. Wang (2018)
10.1038/jid.2012.510
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
P. Sekula (2013)
10.1080/01621459.1987.10478502
Regression Methods for Poisson Process Data
J. Lawless (1987)
10.1016/j.jaad.2014.07.016
Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
M. Kirchhof (2014)
10.4103/0378-6323.41379
Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis.
R. Rai (2008)
10.1056/NEJMoa1013297
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.
M. McCormack (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar